Trial Profile

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ANB-033 (Primary) ; ANB-033 (Primary)
Indications Coeliac disease
Focus Adverse reactions; First in man
Sponsors AnaptysBio

Most Recent Events

07 May 2026 Results presented in a Corporate Presentation of AnaptysBio.
04 Nov 2025 According to an AnaptysBio media release, top-line Phase 1b data anticipated in Q4 2026.
29 Sep 2025 According to an AnaptysBio media release, the company will host a virtual investor event on ANB033 to present initial Phase 1a data in healthy volunteers and celiac disease (CeD) disease biology and Phase 1b trial design.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com